Brief: Suven Life Sciences Says FDA Observed Some Procedures Are Deficient During Medak Unit Inspection
24/04/2018 13:30
April 24 (Reuters) - Suven Life Sciences Ltd SUVP.NS :
* SUVEN LIFE SCIENCES - FDA DURING INSPECTION OF
PASHAMYLARAM,
MEDAK UNIT OBSERVED THERE ARE PROCEDURES FOLLOWED ON CERTAIN
ASPECTS WHICH ARE DEFICIENT
* SAYS CO REVISED STANDARD OPERATING PROCEDURES AS
CORRECTIVE
ACTION
Source text - http://bit.ly/2HW47sz
Further company coverage: SUVP.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees